U:  P:        Forgot Password? Username?
Asthma
A Comparison of SYMBICORT pMDI With Budesonide HFA pMDI in African American Subjects With Asthma. PDF Print E-mail
  • The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
 
A Study of Xolair in Subjects With Moderate to Severe Persistent Asthma (EXTRA) PDF Print E-mail
  • This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Xolair as add-on therapy to high-dose ICS+LABA for the treatment of subjects aged 12-75 years old diagnosed with moderate to severe asthma who are inadequately controlled with high-dose ICS+LABA.
 
An Observational Prospective Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants (32 to 35 Week Gestational Age) - Outcomes and Risk Tracking Study (The Report Study) PDF Print E-mail

This is an observational, prospective study of preterm infants 32 to 35 wGA. Subjects will be screened and entered into the study during their earliest pediatric outpatient visit (routine well-baby visit or unscheduled sick visit), from 01Sep2009 through 31Jan2010 for Season 1, and from 01Sep2010 through 31Jan2011 for Season 2. All subjects will be followed up to the end of their first RSV season (31May). Interval (between-visit) RSV infections, hospitalizations, ED visits, and outpatient LRIs will be assessed during each follow-up visit between the Initial Visit and 31May. When an interval event is reported, medical records/charts will be obtained by the investigator to collect all study-pertinent information, including any RSV testing and results.
 


Privacy PolicyTerms of ServiceLogin